Cambrex, the mall molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has named Tom Loewald as CEO and a member of the company's Board of Directors, effective 7 September.
As previously announced, in the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, Chairman of the Board, Robert Green, Executive VP and Chief Financial Officer, and Samantha Hanley, Senior VP and General Counsel.
Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including Chief Commercial Officer, President of the Analytical Instruments Group, President of the Laboratory Products Group and President of the Laboratory Equipment Division. He currently serves as President of the Flexibles Division of ProAmpac, a leading flexible packaging manufacturer.
Earlier in his career he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the Board of Directors of Harvard BioScience, a global developer, manufacturer and marketer of a broad range of solutions to advance life science.
"Cambrex has a phenomenal reputation for providing unmatched expertise, innovation and customer service across the entire drug lifecycle, and I am thrilled to be joining the company at a time when bringing therapeutics to patients across the globe is more important than ever," said Loewald. "I am eager to get to work, alongside the talented leadership team, to further solidify the company's position as a leader in the CDMO market."
Wayne Hewett, Chairman of the Board of Directors, said: "Tom's deep knowledge of life sciences and manufacturing, and strong commercial, operating and financial focus, make him the ideal leader for Cambrex as we approach this phase of accelerated growth. We are confident that he will be an excellent fit for the company's customer-centric culture and look forward to supporting him and the entire team on the exciting road ahead."